Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.

Saved in:
Bibliographic Details
Title: Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.
Authors: Janjigian YY; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA. Electronic address: janjigiy@mskcc.org., Kawazoe A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Hospital East, Kashiwa, Japan., Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China., Lonardi S; Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Metges JP; CHU Brest-Institut de Cancerologie et d'Hematologie ARPEGO Network, Brest, France., Wyrwicz LS; Department of Oncology and Radiotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland., Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China., Ostapenko Y; Department of Minimally Invasive and Endoscopic Surgery, National Cancer Institute Ukraine, Kyiv, Ukraine., Bilici M; Atatürk University Faculty of Medicine, Department of Medical Oncology, Erzurum, Türkiye., Lowery MA; Department of Medical Oncology, Trinity St James Cancer Institute, Trinity College, Dublin, Ireland., Valderrama A; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Guan Y; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Li K; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Shih CS; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Source: ESMO open [ESMO Open] 2025 Oct; Vol. 10 (10), pp. 105542. Date of Electronic Publication: 2025 Sep 30.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-7029
DOI:10.1016/j.esmoop.2025.105542